logo

For the Inventor, By the Inventor

Slangerup, Denmark

Claus Ulrich Jessen

This inventor holds 7 USPTO granted patents and 2 EPO patents. Top assignee: Novo Nordisk A/s. Active years: 2001-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Claus Ulrich Jessen. Retrieved from https://idiyas.com/inventor/claus-ulrich-jessen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.1

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Vanlose, DK (2001)
  • Vanloese, DK (2001)
  • Vanløse, DK (2004)
  • Slangerup, DK (2014 - 2017)

Company Filing History:

goldMedal7 out of 1,802 
 
Novo Nordisk A/s
 patents

Years Active: 2001-2017

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 9732137 - Semi-recombinant preparation of GLP-1 analogues (2017-08-15),
2. 8791236 - Method of acylating a peptide or protein (2014-07-29),
3. 8637647 - Method of acylating a peptide or protein (2014-01-28),
4. 6784158 - Method for preparing a compound with growth hormone releasing properties (2004-08-31),
5. 6316489 - Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine (2001-11-13),
6. 6281247 - Salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)amide (2001-08-28),
7. 6239163 - Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine (2001-05-29),

Title: The Innovative Contributions of Claus Ulrich Jessen

Introduction

Claus Ulrich Jessen is a notable inventor based in Slangerup, Denmark. With a portfolio encompassing seven patents, Jessen has made significant contributions to the field of biotechnology and pharmaceutical sciences. His work is particularly recognized within the realm of peptide synthesis and modifications.

Latest Patents

Among Jessen's latest inventions is a patent related to the semi-recombinant preparation of GLP-1 analogues. This innovative method combines recombinant expression techniques with chemical peptide synthesis to produce GLP-1 analogues and derivatives that incorporate non-proteogenic amino acids at the N-terminal position. This advancement may have substantial implications for diabetes treatment and metabolic disorders. Another significant patent of his outlines a method for selectively acylating an amino group in a peptide or protein containing multiple reactive nucleophilic functional groups. This technique enhances peptide manipulation and could be pivotal in the development of new therapeutic agents.

Career Highlights

Claus Ulrich Jessen is an integral part of Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. His contributions within the company have not only reinforced its innovative capabilities but also expanded the potential for new drug developments in the complex fields of endocrinology and diabetes management.

Collaborations

Throughout his career, Jessen has collaborated with talented coworkers such as Caspar Christensen and Rune Severinsen. These partnerships have played a crucial role in fostering a collaborative environment that encourages innovation and the development of groundbreaking solutions in healthcare.

Conclusion

Claus Ulrich Jessen’s inventive spirit and dedication to scientific advancement make him a prominent figure in the landscape of modern biotechnology. With multiple patents to his name and a commitment to improving patient outcomes, his work continues to inspire future innovations in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…